Related Experiment Video

Updated: Mar 9, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

8.4K

Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis

Yongxing Gong1, Steven E Schumacher2, Wei H Wu1

  • 1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Neoplasia (New York, N.Y.)
|December 31, 2016
PubMed

Insights

The PARK2 tumor suppressor regulates programmed cell death by controlling BCL-XL, a key apoptotic factor. Loss of PARK2 function in cancer leads to increased BCL-XL, promoting cell survival and proliferation.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • The PARK2 gene's role in Parkinson's Disease and cancer is known, but its precise cellular mechanisms remain unclear.
  • Understanding PARK2's function is crucial for developing targeted cancer therapies.

Purpose of the Study:

  • To elucidate the role of the PARK2 tumor suppressor in regulating programmed cell death.
  • To investigate the relationship between PARK2, BCL-XL, and cancer development.

Main Methods:

  • Analysis of approximately 10,000 tumor genomes to identify genetic correlations.
  • Biochemical assays to study PARK2's interaction with BCL-XL.
  • In vitro and in vivo experiments to assess the impact of PARK2 inactivation on BCL-XL levels and apoptosis.

Main Results:

  • A significant mutual exclusivity was observed between PARK2 loss and BCL2L1 amplification across numerous tumor types.
  • PARK2 directly binds to and ubiquitinates BCL-XL, targeting it for degradation.
  • PARK2 inactivation results in BCL-XL accumulation and impaired apoptosis, dependent on BCL-XL levels.

Conclusions:

  • PARK2 acts as a tumor suppressor by modulating apoptosis through the regulation of BCL-XL.
  • PARK2's antiproliferative effects stem from its control over both cell cycle progression and programmed cell death.
  • The findings highlight a critical pathway involving PARK2 and BCL-XL in cancer pathogenesis.

More Related Videos

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line06:24

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

966
Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal08:00

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

8.0K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K